key: cord-0019342-1n2kes28
authors: Sepriano, Alexandre; Ramiro, Sofia; van der Heijde, Desirée; Landewé, Robert
title: Biological DMARDs and disease modification in axial spondyloarthritis: a review through the lens of causal inference
date: 2021-07-12
journal: RMD Open
DOI: 10.1136/rmdopen-2021-001654
sha: 7314534349a5a76dd664f861ef57da982ab9435e
doc_id: 19342
cord_uid: 1n2kes28

Axial spondyloarthritis (axSpA) is a chronic rheumatic disease characterised by inflammation predominantly involving the spine and the sacroiliac joints. In some patients, axial inflammation leads to irreversible structural damage that in the spine is usually quantified by the modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS). Available therapeutic options include biological disease-modifying antirheumatic drugs (bDMARDs), which have been proven effective in suppressing inflammation in several randomised controlled trials (RCT), the gold standard for evaluating causal treatment effects. RCTs are, however, unfeasible for testing structural effects in axSpA mainly due to the low sensitivity to change of the mSASSS. The available literature therefore mainly includes observational research, which poses serious challenges to the determination of causality. Here, we review the studies testing the effect of bDMARDs on spinal radiographic progression, making use of the principles of causal inference. By exploring the assumptions of causality under counterfactual reasoning (exchangeability, positivity and consistency), we distinguish between studies that likely have reported confounded treatment effects and studies that, on the basis of their design, have more likely reported causal treatment effects. We conclude that bDMARDs might, indirectly, interfere with spinal radiographic progression in axSpA by their effect on inflammation. Innovations in imaging are expected, so that placebo-controlled trials can in the future become a reality. In the meantime, causal inference analysis using observational data may contribute to a better understanding of whether disease modification is possible in axSpA.

Axial spondyloarthritis (axSpA) is characterised by inflammation and pathological new bone formation predominantly involving the spine and the sacroiliac joints (SIJ). Patients with axSpA and structural damage on pelvic radiographs, according to the modified New York criteria, 1 are referred to as radiographic axSpA (r-axSpA) and the others as nonradiographic axSpA (nr-axSpA).

The C reactive protein (CRP) and the Ankylosing Spondylitis Disease Activity Score (ASDAS) are measures of disease activity that quantify systemic inflammation. 2 Bone marrow oedema (BME) on MRI reflects local inflammation in vertebral corners and in the SIJ. 3 Several studies have consistently shown that inflammation (ASDAS, CRP and BME) may lead to new bone formation. [4] [5] [6] [7] [8] [9] [10] [11] Bone biopsy studies and animal models have provided the necessary biological framework, by showing that when BME subsides, it is replaced by a repair tissue with new boneforming capability. 12 13 Non-steroidal anti-inflammatory drugs (NSAIDs) constitute the first-line pharmacological treatment in axSpA. Patients with axial involvement who do not respond to NSAIDs should be treated with biological disease-modifying antirheumatic drugs (bDMARDs). 14 Several randomised controlled trials (RCTs) have shown that tumour necrosis factor alpha inhibitors (TNFi) and interleukin 17 inhibitors (IL-17i) are effective in suppressing inflammation and Key messages ► The evaluation of the structural effect of biological disease-modifying antirheumatic drugs (bDMARDs) in axial spondyloarthritis (axSpA) by a randomised controlled trial is currently unfeasible. ► Several observational studies addressed this enduring and highly clinically relevant question. ► Observational research can yield causal treatment effects if key causal assumptions are met. ► Causal inference principles indicate that bDMARDs might slow spinal structural progression in axSpA by suppressing inflammation.

alleviating symptoms, both in r-axSpA and nr-axSpA. 15 Since inflammation may trigger structural damage, therapies that successfully suppress the former should, in theory, stop or at least retard the latter. However, after years of research, the structural effects of bDMARDs remain under debate. 16 In some studies, bDMARDs did not appear to have structural effects, while in others, more positive results were found. [17] [18] [19] We will explore this inconsistency by reviewing the literature under the principles of causal inference. We here use counterfactual reasoning as proposed by Rubin, 20 Balke and Pearl 21 and as recently revised by Gvozdenović et al. 22 Treatment effects are considered causal, under the proviso of certain assumptions: exchangeability, positivity and consistency. We will start by defining causality under these assumptions. We will then use this definition as a benchmark to determine the likelihood of causality of the treatment effects from studies evaluating the structural effects of bDMARDs in axSpA. We conclude by anticipating the major advances expected in the field in the near future.

Let us consider an individual patient with axSpA who starts a bDMARD. We quantify the patient's spinal damage before the start of treatment and after a certain period of time and then record the change (factual outcome). Now, let us consider the same patient in a 'counterfactual world', in which no treatment was given. We measure the initial damage and again the change (counterfactual outcome). Because the patient is the same, it is obvious that any difference between the factual and the counterfactual outcome must be caused by the treatment. Obviously, we will never observe the counterfactual outcome, so it is impossible to ascertain causality in an individual patient.

Let us now consider a population of patients with axSpA ( figure 1A ). In the hypothetical 'world 1', all patients receive a bDMARD. We follow them all and determine their mean progression (potential outcome 1). We then hypothetically follow the same population of patients but give them a different drug ('world 2') and determine their mean progression (potential outcome 2). Since the population is the same, it is obvious that any difference between outcomes 1 and 2 is caused by the treatment. Even though we cannot really observe the two potential outcomes, we can estimate their expected mean values, which is what we do in RCTs.

In an RCT, randomisation ensures that, at the group level, patients who actually get the bDMARD and those who get a comparator (usually placebo) have the same characteristics of their source population and, consequently, are similar to each other. We say that treatment allocation is ignorable (it does not matter who gets what) and that the two groups are exchangeable (have the same characteristics). Had the patients who actually got the 50 The notation below each figure indicates either a mean difference or a risk ratio as measures of the treatment effect. For instance, in an observational study, we determine the difference between the mean value of mSASSS among patients on bDMARDs (Y|T=1) and the mean value of mSASSS among the controls (Y|T=0). We might also determine the risk of developing a new syndesmophyte among those on bDMARD (Y|T=1), relative (divided) to the risk of a new syndesmophyte in controls (Y|T=0). Unlike randomised controlled trials, the treatment effect is biased because each group is not representative of the entire source population and groups are therefore not exchangeable. axSpA, axial spondyloarthritis; bDMARD, biological disease-modifying antirheumatic drug; mSASSS; modified Stoke Ankylosing Spondylitis Spinal Score.

bDMARD (factual world) hypothetically not got it (counterfactual world), they would have the same potential outcome as those on the comparator. Measuring the outcome in two groups formed by randomisation is the same as measuring the outcome in all patients under hypothetical 'world 1 and 2' conditions.

In addition to exchangeability, causal claims also imply the positivity assumption, which is met when all patients, irrespective of their characteristics, have a probability greater than zero to be allocated to the treatment or to the comparator. Finally, both the intervention and the comparator need to be well defined, and their definition must not change during the time in which the treatment effect is being evaluated (consistency assumption).

The three causal assumptions are usually (but not always) met in RCTs, and that is why they are the gold standard in causal inference. Of note, modern trials in rheumatology, such as treat-to-target trials and (other) strategy trials will meet the criteria of exchangeability and positivity but fail the consistency criterion since the content of the treatment may vary over time.

The assessment of causal treatment effects implies the use of valid outcome measures. Spinal radiography has been the imaging modality of choice to measure structural damage in patients with axSpA. The modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) is the most often used score to measure spinal radiographic progression and performs better than any other score in terms of reliability, validity and sensitivity to change, both in patients with r-axSpA and nr-axSpA. 23 24 Even though the mSASSS is the score with best sensitivity to change, it still takes ≥2 years for a change to be observable, at the group level, in patients with r-axSpA. 25 Progression is even slower in early axSpA. 26 Slow progression renders RCTs aiming at testing causal structural effects rather unfeasible. Patients in an RCT are all, by design, eligible to receive the treatment under study (eg, all have high levels of disease activity). As mentioned, bDMARDs reduce the signs and symptoms of the disease. It is therefore unethical to deprive patients from an effective therapy they would likely benefit from, for the time it takes to evaluate a potential structural effect. One alternative is to observe the effect of treatment as prescribed in clinical practice, a setting, however, in which the causality assumptions will less likely hold.

Randomisation ensures that differences in outcomes between groups are fully explained by treatment. The same cannot be said if treatment prescription is not random but made by a clinician. Let us consider the population of patients with axSpA. In the factual world, only a fraction of patients, those who have failed-or are intolerant to-conventional treatment, are eligible to receive bDMARDs (figure 1B). That means treated patients usually have more severe disease than untreated patients. Treatment allocation is, therefore, not ignorable, and treated and untreated groups are not exchangeable. This problem is often referred to as 'confounding by indication'.

A confounder ('C') influences both the treatment decision ('T') and the outcome ('Y') and is not in the causal pathway between both (figure 2). For instance, patients with higher pretreatment levels of ASDAS ('C') are more likely to receive a bDMARD ('T') than those with lower levels. Also, higher ASDAS may lead to higher mSASSS ('Y'). Thus, in a non-randomised experiment, bDMARDs may affect the mSASSS due to (1) a causal effect of the drug on mSASSS ('front-door' path: T→Y) or (2) a spurious effect of the drug on mSASSS through ASDAS ('back-door' path: T←C→Y). In an RCT, randomisation 'closes' all measured and unmeasured 'back doors' (figure 2A). In an observational study, the 'back doors' keep open, which may lead to spurious effects ( figure 2B ).

In addition to ASDAS (also CRP and BME), the presence of damage at baseline, male gender, longer disease duration and smoking all associate with radiographic progression. 8 9 27 These characteristics are confounders if they also influence the decision to start a bDMARD. One possible solution is to 'fix' the values of confounders between treated and controls and estimate the so-called average marginal effect (AME) (figure 2C). Methods to estimate the AME, by 'back-door' adjustment, that is, methods used to take 'confounding by indication' into account, include matching, stratification, regression adjustment, propensity score (PS) adjustment and inverse probability of treatment weighting.

Under fixed values of all confounders, and assuming no unmeasured confounding, the treated and untreated are fully exchangeable. However, this alone does not suffice to guarantee causal treatment effects. In observational research, treatment groups are not necessarily consistently defined. Bias may also occur if patients under treatment who are included in studies, and are therefore compared with controls, have relevant prognostic dissimilarities with those who are not. If that happens, the positivity assumption is likely violated as patient's characteristics are constraining treatment allocation (eg, if patients with worse prognostic factors have zero probability to be treated).

Disease modification in axSpA: observational research Studies with equal exposure to treatment and without a comparator After the completion of an RCT, patients on placebo usually switch to the active drug and, together with those on treatment from the start, are followed in open-label extensions (OLE), provided they meet certain inclusion criteria. The structural effect of bDMARDs in axSpA have, thus far, been evaluated in OLE with patients continuously exposed to TNFi for up to 10 years. All studies included patients with r-axSpA, except for one RMD Open RMD Open RMD Open also including patients with nr-axSpA. The number of patients in the original RCTs ranged from 84 to 325 and those in the corresponding OLEs (ie, with complete follow-up and imaging data) from 17 to 93. [28] [29] [30] OLEs consistently report minimal change in the mSASSS. In one 4-year OLE, no meaningful change in mSASSS was observed in patients with nr-axSpA. 30 In the same study, the change in mSASSS was higher in the first 2 years than in the last 2 years in patients with r-axSpA (0.8 vs 0.4), suggesting a late-onset structural benefit.

In studies without a comparator, which is the case in OLE, it is impossible to address the exchangeability assumption. The following counterfactual question remains unanswered: had the patients not received the bDMARD, would their average change in mSASSS be different than the observed change? In addition, the few patients that continue on treatment and are therefore included in the OLE are not necessarily representative of the larger population of patients eligible for bDMARDs from the corresponding RCTs. The positivity assumption is most likely violated, since patients with milder disease are, arguably, more likely to stay on treatment in the OLE (right censoring bias). On the contrary, the consistency assumption is likely to hold, as all patients receive the same drug over the entire follow-up. Even if patients initially on placebo are included, this is usually for a welldefined and (very) short period of time.

Comparative studies with equal exposure to treatment The large majority of studies evaluating the structural effect of bDMARDs included a comparator, and among these, most were done in a setting in which all patients had to be on bDMARD, or on the comparator, continuously over the entire study (time-fixed treatment). Confounders, when considered, were evaluated at baseline before the start of treatment (time-fixed confounders), and the outcome was assessed at the end (time-fixed outcome).

Studies with time-fixed treatment compared patients with r-axSpA on bDMARD to either ineligible patients or patients in whom bDMARDs were not an option (eg, historical cohorts). Table 1 In three studies, patients on TNFi from OLEs were compared with patients not receiving TNFi from the Outcome in AS International Study (OASIS) historical cohort. [31] [32] [33] As expected, patients on TNFi had worse prognostic factors (eg, higher levels of disease activity and damage) than patients from OASIS. Thus, patients on TNFi were compared with patients from OASIS who would have fulfilled the inclusion criteria of the OLE. The effect size was zero in the matched population (table 1) as well as in stratified and adjusted analyses. The absence of a structural effect was also reported in other studies comparing TNFi to no TNFi, as well as IL-17i to NSAIDs, up to 2 years of follow-up. [34] [35] [36] [37] One study comparing 22 patients from an 8-year OLE with a historical cohort has shown slower progression ; red arrows, biasing paths ('back doors'); crossed red arrows, closed biasing paths (eg, by randomisation in A and adjustment in C). T b , treatment status at baseline (yes/no); C b , a set of observed pretreatment confounders at baseline; Ub, a set of unobserved pretreatment confounders at baseline; Y f , outcome at follow-up. The notation below each DAG indicates either a mean difference or a risk ratio as measures of the treatment effect. The average marginal effect is the equivalent of a causal effect of a randomised controlled trial under the assumption that all confounders had been measured and adjusted for (no unmeasured confounding). 

with TNFi versus no TNFi after the fourth year of follow-up, adjusting for the mSASSS at baseline. 38 In two cohort studies, patients on TNFi were compared with those not on TNFi after PS matching, with one showing a positive structural effect and the other no effect. 39 40 Not all studies evaluating the effect of 'time-fixed' exposure to bDMARDs addressed confounding, and those that did considered only the effect of baseline variables (mostly damage). In studies that span for several years, it is arguable whether handling baseline confounding suffices for full exchangeability. Under null (or partial) exchangeability, it is reasonable to expect worse prognostic factors to dominate in the treated and therefore for underestimated structural effects. In addition, right censoring bias is likely, since patients had to keep the drug for several years to qualify for inclusion, thus violating the positivity assumption. Overestimation of the treatment effect is likely, if patients with better prognosis are preferentially selected, since the comparison is made in a population most likely resembling the patients eligible to receive the control rather than the patients eligible for the treatment. Interpreting the direction of residual bias is difficult if neither assumption holds. Finally, the consistency assumption is likely not met when patients on bDMARD are compared with those not on bDMARD, as 'no bDMARD' is poorly defined and is likely to vary over time.

Comparative studies with variable exposure to treatment In recent studies, patients were evaluated in regular intervals. In order to be included, they only had to be followed during one period. For instance, a patient could only start a bDMARD in the second interval and then keep it until the end of the study (eg, six intervals in total, five on bDMARD). Another patient could have been treated since baseline but was lost to follow-up somewhere in the end of the first interval, thus 'contributing' with data to only one of six possible intervals. In this type of study, with unequal exposure to bDMARDs ('time-varying'), the AME is the combined effect of treatment considering all available intervals, estimated with methods such as generalised estimating equations, that handle repeated observations per patient.

In studies with 'time-varying' treatment, treatment status is recorded at the start-and the outcome at the end-of each interval. Measures of disease activity (eg, ASDAS), damage (eg, mSASSS) and comedication (eg, NSAIDs), among other variables, are also recorded per interval. These features can be time-varying confounders, if they influence the prescription of bDMARDs at the start-and the outcome at the end-of each interval ( figure 3A) . ASDAS is also thought to mediate the structural effect of bDMARDs in axSpA. Importantly, a mediator, different to a confounder, resides in the causal pathway between the treatment and the outcome (figure 3B). Testing for mediation implies decomposing the total effect into (1) the direct effect of bDMARDs The studies evaluating the effect of time-varying treatment with bDMARDs on spinal radiographic progression are summarised in table 3. All studies tested only TNFi in patients with r-axSpA. 39 42-46 Follow-up ranged from 4 to 18 years; however, most patients had only contributed to few intervals. Both baseline and time-varying pretreatment confounders were considered, including measures of disease activity, damage and comedication. The total effect, adjusting for pretreatment confounders, was significant in all studies (table 3) . Two studies tested whether ASDAS at the start of the interval was a timevarying mediator. 44 46 Another study tested the mediating effect of the average value of CRP per interval. 45 All three studies have shown that bDMARDs inhibit structural progression indirectly by lowering the levels of ASDAS (or CRP). In two of these studies, the direct effect of bDMARDs was not statistically significant, 44 45 suggesting that the structural benefit was solely explained by the reduction of disease activity. In the third study, however, the direct effect of bDMARDs remained statistically significant after adjusting for ASDAS. 46 Almost all studies reporting the time-varying structural effect of TNFi have handled time-varying confounding. Even though residual confounding is still a possibility, it can be argued that its likelihood is lower as compared with other types of studies discussed above. A claim of (full) exchangeability is therefore the only logical consequence. In addition, studies that allow a variable exposure to the treatment will minimise the risk of right censoring; both patients with a worse prognosis, who may be followed in fewer intervals, and those with a better prognosis, who may be followed in several intervals, can be included in the analysis. However, most studies had most patients followed for only a few intervals, which might render the positivity assumption less likely had a better balance been achieved. Finally, almost all studies compared treatment with TNFi with no TNFi, thus compromising the consistency assumption.

The effect of bDMARDs on spinal radiographic progression in patients with axSpA has been extensively studied over the past 15 years. Studies without a comparator suggest that bDMARDs may slow progression, but a claim of causality is implausible in such a setting. The exchangeability assumption is not even possible to assess, and positivity is unlikely due to right censoring bias. The likelihood of causality increases in studies with a comparator. However, studies requiring all patients to stay on treatment during the entire study are also susceptible to right censoring bias (worst patients drop out). In these studies, confounding was only considered at baseline limiting the likelihood of exchangeability. It is therefore difficult to interpret both the negative, short-term (≤2 years), studies and the inconsistent results from studies with longer follow-up. Studies with unequal (time-varying) exposure to treatment are the most likely to yield causal structural effects. Their design protects, to some extent, against 'right censoring', thus making positivity more likely. In addition, these studies handle inherently time-varying confounders as such, thus increasing the chance of (full) exchangeability (table 4) .

In all studies in the top of 'causal hierarchy', treatment with TNFi consistently reduced radiographic progression For the purpose of illustration, the DAGs are simplified (absent arrows) by making the following (unlikely to hold) assumptions: Y t+1 does not influence T t+1 ; Y t+1 does not influence Y t+2 ; C t does not influence C t+1 . Black arrows, associations of interest ('front doors'); red arrows, biasing paths ('back doors'); T t , treatment status (yes/no) at the start of the first interval; T t+1 , treatment status at the start of the second interval; C t , a set of pretreatment confounders at the start of the first interval; C t+1 , a set of pretreatment confounders at the start of the second interval; Y t+1 , outcome at end of the first interval; Y t+2 , outcome at the end of the second interval; M t* , mediator measured after treatment assignment and before outcome assessment on the first interval; M t+1* , mediator measured after treatment assignment and before outcome assessment on the second interval.

as compared with no treatment. This effect was either partially or entirely mediated by their effect on inflammation. A causal inflammation-mediated effect is in line with the evidence that inflammation drives structural progression and strongly argues in favour of a treat-totarget strategy in axSpA. In one study, a direct effect, that means through other (unknown) mechanisms, was also found. Although not implausible, the fluctuating nature of inflammation in axSpA can also explain this finding. 'No detectable inflammation' (eg, no BME or ASDAS <1.3) is not necessarily the same as 'no inflammation present'. Despite consistent results, studies with 'timevarying' treatment are not without limitations. Future studies addressing their limitations, as exposed here, will likely contribute to a better understanding of the structural effect of bDMARDs in axSpA.

Recent data suggest that the CT Syndesmophyte Score (CTSS) is more sensitive to change than the mSASSS. 47 Low-dose CT, and other imaging innovations, may render RCTs testing structural effects feasible in the future, by decreasing the time needed to observe a treatment effect. Of note, observational studies using CTSS as a measure of structural damage face similar challenges, as studies using the mSASSS, in identifying causal treatment effects. Trials comparing TNFi to IL-17i are also expected but will only be informative if their structural effects really differ. 16 In the absence of an RCT, however, causal inference from observational research can still be informative. 48 New causal analyses done with well-defined comparators will likely clarify the effect of TNFi on mSASSS in r-axSpA as well as in nr-axSpA and also for drugs other than TNFi.

Directed acyclic graphs (DAGs) are powerful instruments in causal inference and will likely become more common in the rheumatological literature in the coming years. The model represented in a DAG (eg, figure 3) is causal, provided its underlying assumptions (arrows and nods) hold. This is why DAGs are also named structural causal models. In addition to 'back-door' adjustment, other methods such as 'front-door' adjustment with 'shielded mediators' and instrumental variables can be used to handle confounding in structural causal models. 49 Is disease modification possible in axSpA? The definitive answer will likely be given in the next few years, by RCTs (when using a different structural damage assessment method, eg, with low-dose CT), but preceded by thorough theoretical causal analysis.

Collaborators None.

Contributors All authors drafted the text and approved the final version for publication.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors. Assumption is very unlikely (-), unlikely (+/-) and likely (+) to be met.

Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the new York criteria

Development of an ASASendorsed disease activity score (ASDAS) in patients with ankylosing spondylitis

The role of imaging in the diagnosis and management of axial spondyloarthritis

Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? a long-term observational study using MRI and conventional radiography

Sacroiliac radiographic progression in recent onset axial spondyloarthritis: the 5-year data of the DESIR cohort

Mri vertebral corner inflammation followed by fat deposition is the strongest contributor to the development of new bone at the same vertebral RMD Open RMD Open RMD Open corner: a multilevel longitudinal analysis in patients with ankylosing spondylitis

High disease activity according to the ankylosing spondylitis disease activity score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis: results from the German spondyloarthritis inception cohort

Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis

Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort

Disease activity is associated with spinal radiographic progression in axial spondyloarthritis independently of exposure to tumour necrosis factor inhibitors

Mri inflammation at the vertebral unit only marginally predicts new syndesmophyte formation: a multilevel analysis in patients with ankylosing spondylitis

Granulation tissue Eroding the Subchondral bone also promotes new bone formation in ankylosing spondylitis

Inflammation-Driven bone formation in a mouse model of ankylosing spondylitis: sequential not parallel processes

2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis

Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review Informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis

Inhibition of spinal bone formation in AS: 10 years after comparing adalimumab to OASIS

The effect of tumour necrosis factor inhibitors on radiographic progression in axial spondyloarthritis: a systematic literature review

Biologic therapy and spinal radiographic progression in patients with axial spondyloarthritis: a structured literature review

Effect of therapy on radiographic progression in axial spondyloarthritis: a systematic review and meta-analysis

Estimating causal effects of treatments in randomized and nonrandomized studies

Counterfactual probabilities: computational methods, bounds and applications

Causal inference concepts applied to three observational studies in the context of vaccine development: from theory to practice

Which scoring method depicts spinal radiographic damage in early axial spondyloarthritis best? five-year results from the DESIR cohort

What is the most appropriate radiologic scoring method for ankylosing spondylitis? A comparison of the available methods based on the outcome measures in rheumatology clinical trials filter

Evolution of radiographic damage in ankylosing spondylitis: a 12 year prospective follow-up of the OASIS study

Spinal radiographic progression in early axial spondyloarthritis: five-year results from the DESIR cohort

Rate and predisposing factors for Sacroiliac joint radiographic progression after a two-year follow-up period in recent-onset spondyloarthritis

Etanercept in the longterm treatment of patients with ankylosing spondylitis

Physical function and spinal mobility remain stable despite radiographic spinal progression in patients with ankylosing spondylitis treated with TNF-α inhibitors for up to 10 years

Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial

Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis

Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept

Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years

Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab

Spinal radiographic progression over 2 years in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison

The paradoxical effects of TNF inhibitors on bone mineral density and radiographic progression in patients with ankylosing spondylitis

Resolution of inflammation following treatment of ankylosing spondylitis is associated with new bone formation

Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis

The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis

Radiographic progression in patients with ankylosing spondylitis according to tumor necrosis factor blocker exposure: observation study of Korean spondyloarthropathy registry (oskar) data

Interpretation and identification of causal mediation

OP0198 combined effects of tumour necrosis factor inhibitors and NSAIDs on radiographic progression in ankylosing spondylitis

Tumour necrosis factor inhibitors slow radiographic progression in patients with ankylosing spondylitis: 18-year real-world evidence

Tnf blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss clinical quality management cohort

Impact of tumor necrosis factor inhibitor versus nonsteroidal antiinflammatory drug treatment on radiographic progression in early ankylosing spondylitis: its relationship to inflammation control during treatment

Tumor necrosis factor inhibitors reduce spinal radiographic progression in patients with radiographic axial spondyloarthritis: a longitudinal analysis from the Alberta prospective cohort

Low-Dose CT detects more progression of bone formation in comparison to conventional radiography in patients with ankylosing spondylitis: results from the SIAS cohort

COVID-19-induced hyperinflammation, immunosuppression, recovery and survival: how causal inference may help draw robust conclusions

The book of why: the new science of cause and effect

Causal Inference: What If

The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial

Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the measure 1 study

Provenance and peer review Commissioned; externally peer reviewed.Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http:// creativecommons. org/ licenses/ by-nc/ 4. 0/.

Alexandre Sepriano http:// orcid. org/ 0000-0003-1954-0229 Sofia Ramiro http:// orcid. org/ 0000-0002-8899-9087 Desirée van der Heijde http:// orcid. org/ 0000-0002-5781-158X Robert Landewé http:// orcid. org/ 0000-0002-0577-6620